The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials

Pain

Volumn 78, Issue 3, 1998, Pages 157-169

  Fulfaro, F ^a   Casuccio, A ^b   Ticozzi, C ^c   Ripamonti, C ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Bisphosphonates; Bone metastases; Cancer pain; Palliative therapy; Quality of life; Randomized trial

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ANALGESIC ACTIVITY; BONE METASTASIS; BONE PAIN; BREAST CANCER; COMPLIANCE (PHYSICAL); DATA BASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERCALCEMIA; MULTIPLE MYELOMA; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW;

EID: 0032406920     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(98)00135-3     Document Type: Article

References (101)

1. Adami S. Bisphosphonates in prostate carcinoma. Cancer. 80:1997;1674-1679.
2. Adami S., Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res. 116:1989;67-72.
3. Belch A.R., Bergsagel D.E., Wilson K.et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J. Clin. Oncol. 9:1991;1397-1402.
4. Berenson, J.R., Lichtenstein, A., Porter, L., et al., Efficacy of Pamidronate in reducing skeletal events in patients with advanced multiple myeloma, N. Engl. J. Med., 334 (1996a) 488-493.
5. Berenson, J.R., Lipton, A., Rosen, L.S., et al., Phase I clinical study of a new bisphosphonate, Zoledronate (CGP-42446), in patients with osteolytic bone metastases, Blood, 88 (Suppl. 1) (1996b) 586a.
6. Berenson J.R., Rosen L., Vescio R.et al. Pharmacokinetics of Pamidronate Disodium in patients with cancer with normal or impaired renal function. J. Clin. Pharmacol. 37(4):1997;285-290.
7. Berenson J.R., Lichtenstein A., Porter L.et al. Long-term Pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Clin. Oncol. 16:1998;593-602.
8. Biermann W.A., Cantor R.I., Fellin F.M.et al. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast. Bone. 12(Suppl. 1):1991;37-42.
9. Body J.J., Dumon J.C., Gineyts E., Delmas P.D. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br. J. Cancer. 75:1997;408-412.
10. Boissier S., Magnetto S., Frappart L.et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57(18):1997;3890-3894.
11. Bonde M., Qvist P., Christiansen C.et al. Applications of an enzyme immunoassay for a new marker of bone resorption (crosslaps): follow-up or hormone replacement therapy and osteoporosis risk assessment. J. Clin. Endocrinol. Metab. 80:1995;864-868.
12. Bonica J.J. Management of cancer pain. Acta Anaest. Scand., Suppl. 74:1982;75-82.
13. Boonekamp P.M., van der Wee-Pals L.J.A., van Wijk-van Lennep M.L., Thesing C.W., Bijvoet O.L.M. Two modes of action of bisphosphonates or osteoclastic resorption of mineralized matrix. Bone Mineral. 1:1986;27-39.
14. Brescia F.T., Adler D., Gray G.et al. Hospitalized advanced cancer patients: a profile. J. Pain Symptom Manage. 5:1990;221-227.
15. Cantrill J.A., Buckler H.M., Anderson D.C. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisophonate (APD) for the treatment of Paget's disease of bone. Ann. Rheumatol. Dis. 45:1986;1012-1018.
16. Cascinu S., Casadei V., Del Ferro E., Alessandroni P., Catalano G. Pamidronate in patients with painful bone metastases, who failed initial treatment with hormone and/or chemotherapy. Support. Care Cancer. 4:1996;31-33.
17. Clarke, N.W., McClure, J. and George, N.J.R., Clinical and metabolic effects of disodium Pamidronate in metastatic prostate cancer. In: O.L.M. Bijvoet and A. Lipton (Eds.), Osteoclastic Inhibition in the Management of Malignancy-Related Bone Disorders, Hogrefe and Huber, Toronto, 1991, pp. 54-63.
18. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br. J. Cancer. 55:1987;61-66.
19. Coleman, R.E., Assessment of response to treatment. In: R.D. Rubens and I. Fogelman (Eds.), Bone Metastases: Diagnosis and Treatment, Springer-Verlag, London, 1991, pp. 99-120.
20. Coleman R.E. Evaluation of bone disease in breast cancer. Breast. 3:1994;73-78.
21. Coleman R.E., Vinholes J., Abbey M.E., Purohit O.P. Double-blind randomised trial of pamidronate (Aredia) for the palliative treatment of metastatic bone disease. Proc. Am. Soc. Cin. Oncol. 15:1996;528.
22. Conte P.F., Latreille J., Mauriac L.et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous Pamidronate: results from a multinational randomized, controlled trial. J. Clin. Oncol. 14:1996;2552-2559.
23. Coombes R.C., Dady P., Parsons C.et al. Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer. 52:1983;610-614.
24. de Haes J.C.J.M., van Knippenberg F.C.E., Neijt J.P. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam symptom checklist. Br. J. Cancer. 62:1990;1034-1038.
25. Dodwell D.J., Howell A., Ford J. Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. Br. J. Cancer. 61:1990;123-125.
26. Dodwell D.J. Malignant bone resorption: cellular and biochemical mechanisms. Ann. Oncol. 3:1992;257-262.
27. Elomaa I., Kylmala T., Tammela T.L.J.et al. Effect of Clodronate on bone pain. A controlled study in patients with metastatic prostate cancer. Int. Urol. Nephrol. 24:1992;159-161.
28. Emonds-Alt X., Breliére J.-C., Ronucci R. Effects of 1-hydroxyethylidene-1,1-bisphosphonate and (chloro-4-phenyl)thiomethylene bisphosphonic acid (SR 41319) on the mononuclear cell factor-mediated release of neutral proteinases by articular chondrocytes and synovial eels. Biochem. Pharmacol. 34:1985;4043-4049.
29. Ernst D.S., MacDonald R.N., Paterson A.H.G., Jensen J., Bruera E. A double-blind cross-over trial of IV Clodronate in metastatic bone pain. J. Pain Symptom Manage. 7:1992;4-11.
30. Ernst, D.S., Brasher, P., Hagen, N., et al., Controlled trial of intravenous clodronate in patients with metastatic bone disease and pain, Proc. Am. Soc Clin. Oncol., 1: (1994) 431 abstr. 1478.
31. Ernst D.S., Brasher P., Hagen N.et al. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J. Pain Symptom Manage. 13:1997;319-326.
32. Felix R., Bettex J.-D., Fleisch H. Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells. Calcif. Tissue Int. 33:1981;549-552.
33. Fitton A., McTavish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 41:1991;289-318.
34. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcemic and metastatic bone disease. Drugs. 42:1991;919-944.
35. Fleisch H. Bisphosphonates: mechanisms of action and clinical use in osteoporosis - an update. Horm. Metab. Res. 29:1997;145-150.
36. Fraser T.R., Ibbertson H.K., Holdaway I.M.et al. Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-isphosphonate): a comparison with combined calcitonin+EHDP (1-hydroxyethylidene-1,1-bisphosphonate). Aust. N.Z. J. Med. 14(6):1984;811-818.
37. Green J.R., Muller K., Jaeggi K.A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Mineral. Res. 9:1994;745-750.
38. Hanson D.A., Weis M.A.E., Bollen A.M.et al. A specific immunoassay for monitoring human bone resorption: quantification of type I collagen cross-linked N-telopeptides in urine. J. Bone Mineral. Res. 7:1992;1251-1258.
39. Hayward J.L., Carbone P.P., Heuson J.C.et al. Assessment of response to therapy in advanced breast cancer. Eur. J. Cancer Clin. Oncol. 13:1977;89-94.
40. Heim M.E., Clemens M.R., Queisser W.et al. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: a muticenter study. Onkologie. 18:1995;439-448.
41. Hortobagyi G.N., Theriault R.L., Porter L.et al. Efficacy of Pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 335:1996;1785-1791.
42. Hughes D.E., Wright K.R., Uy H.L.et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Mineral. Res. 10:1995;1478-1487.
43. Jodrell D.I., Iveson T.J., Smith I.E. Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene disphosphonate. Lancet. 1 (8533):1987;622.
44. Kanis J.A., O'Rourke N., McCloskey E.V. Consequences of neoplasia-induced bone resorption and the use of Clodronate. Int. J. Oncol. 5:1994;713-731.
45. Kanis T.A., Poweles T., Paterson A.H.G., McCloskey E.V., Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 19:1996;663-667.
46. Kylmala T., Taube T., Tammela T.L.et al. Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer. Br. J. Cancer. 76:1997;939-942.
47. Laasko M., Lahtinen R., Virkkunen P., Elomaa I. Subgroup and cost-benefit analysis of the Finnish multicentre trial of Clodronate in multiple myeloma. Br. J. Haematol. 87:1994;725-729.
48. Lahtinen R., Laasko M., Palva I., Virkkunen P., Elomaa I. Randomized placebo-controlled multicentre trial of Clodronate in multiple myeloma. Lancet. 340:1992;1049-1052.
49. Leyvraz S., Hess U., Flesch G.et al. Pharmacokinetics of Pamidronate in patients with bone metastases. J. Natl. Cancer Inst. 84:1992;788-792.
50. Lipton A., Glover D., Harvey H.et al. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann. Oncol. 5:1994;S31-S35.
51. Lipton A., Hershey P.A., Theriault R.et al. Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg Pamidronate infusions. Proc. Am. Soc Clin. Oncol., abstr. 16:1997;152-531.
52. McBride W.H. Phenotype and functions of intratumoural macrophages. Biochem. Biophys. Acta. 865:1986;27-41.
53. McCloskey E.V., Yates A.T.P., Beneton M.N.C.et al. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone. 8(Supp. 1):1987;S35-S41.
54. McCloskey E.V., MacLennan I.C.M., Drayson M.et al. Effect of clodronate on progression of skeletal disease in multiple myelomatosis. Eur. J. Cancer. 31A:1995;S162.
55. Mercadante S. Prevalence, causes and mechanisms of pain in home-care patients with advanced cancer. Pain Clin. 7:1994;131-136.
56. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 69:1997;1-18.
57. Morgan D., Monod A., Russell R., Fleisch H. Influence of dichloromethylene diphosphonate (Cl2MDP) and calcitonin on bone resorption, lactate production and phosphatase and pyrophosphatase content of mouse calvaria treated with parathyroid hormone in vitro. Calcif. Tissue Res. 13:1973;287-294.
58. Muhlbauer R.C., Bauss F., Schenk R.et al. BM 21 0955, a potent new bisphosphonate to inhibit bone resorption. J. Bone Mineral. Res. 6:1991;1003-1011.
59. Mundy G.R. Hypercalcemia of malignancy revisited. J. Clin. Invest. 82:1988;1-6.
60. Niskikawa M., Akatsu T., Katayama Y.et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone. 18:1996;9-14.
61. Nussbaum, S.R., Younger, J., Vandepol, C.J., et al., Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages, Am. J. Med., 95 (1993a) 297-304.
62. Nussbaum, S.R., Warrell, R.P., Jr., Rude, R., et al., Dose-response study of alendronate disodium for the treatment of cancer-associated hypercalcemia, J. Clin. Oncol., 11 (1993b) 1618-1623.
63. Ohya K., Yamada S. R.an, Felix R., Fleisch H. Effect of bisphosphonates on prostaglandin synthesis by rat bone cells and mouse calvaria in culture. Clin. Sci. 69:1985;409-411.
64. Oken M.M., Creech R.H., Tormey D.C.et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:1982;649-655.
65. O'Rourke N.P., McCloskey E.V., Houghton F., Huss H., Kanis J.A. Double-blind, placebo controlled, dose-response trial of oral clodronate in patients with bone metastases. J. Clin. Oncol. 13:1995;929-934.
66. Paterson A.H.G. Bone metastases in breast cancer, prostate cancer and myeloma. Bone. 8(Suppl. 1):1987;17-22.
67. Paterson A.H.G., Powles T.J., Kanis J.A.et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 11:1993;59-65.
68. Paterson A.H.G. Should bisphosphonates be standard therapy for bone pain? Support. Care Cancer. 5:1997;200-204.
69. Pecherstorfer, M., Herrmann, Z., Body, J.J., et al., Randomized phase II trial comparing different doses of the bisphosphonate Ibandronate in the treatment of hypercalcemia of malignancy, J. Clin. Oncol., 14 (1996a) 268-276.
70. Pecherstorfer, M., Ludwig, H., Schlosser, K., et al., Administration of the bisphosphonate Ibandronate (BM 21 0955) by intravenous bolus injection, J. Bone Mineral. Res., 11 (1996b) 587-593.
71. Purohit O.P., Anthony C., Radstone C.R., Owen J., Coleman R.E. High-dose intravenous Pamidronate for metastatic bone pain. Br. J. Cancer. 70:1994;554-558.
72. Ralston S.H., Gallacher S.J. .Pa, Patel U.et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet. 2 (8673):1989;1180-1182.
73. Richards M.A., Brayser S., Gregory W.M., Rubens R.D. Advanced breast cancer: use of resources and cost implications. Br. J. Cancer. 67:1993;856-860.
74. Ripamonti, C., Fulfaro, F., Ticozzi, C., Casuccio, A. and DeConno, F., The role of Pamidronate Disodium in the treatment of metastatic bone disease, Tumour, 1998, in press.
75. Robertson A.G., Reed N.S., Ralston S.H. Effect of oral Clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J. Clin. Oncol. 13:1995;2427-2430.
76. Rossleigh M.A., Lovegrove F.T.A., Reynolds P.M., Byrne M.J., Whitney B.P. The assessment of response to therapy of bone metastases in breast cancer. Aust. N.Z. J. Med. 14:1984;19-22.
77. Sabatini M., Chavez J., Mundy G.R., Bonewald L.F. Stimulation of tumour necrosis factor release from monocytic cells by the A375 human melanoma via granulocyte-macrophage colony-stimulating factor. Cancer Res. 50:1990;2673-2678.
78. Sahni M., Guenther H.L., Fleisch H., Collin P., Martin T.J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest. 91:1993;2004-2011.
79. Sauty A., Pecherstorfer M., Zimmer-Roth I.et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone. 18:1996;133-139.
80. Selander K.S., Monkkonen J., Karhukorpi E.-K.et al. Characteristics of Clodronate-induced apoptosis in osteoclasts and macrophages. Mol. Pharmacol. 50:1995;1127-1138.
81. Shinoda H., Adamek G., Felix R.et al. Structure-activity relationship of various bisphosphonates. Calcif. Tissue Int. 35:1983;87-99.
82. Shipman C.M., Rogers M.J., Apperley J.F., Russell R.G.G., Croucher P.I. Bisphosphonates induce apoptosis in human myeloma cells; a novel antitumour activity. Br. J. Haematol. 98:1997;665-672.
83. Singer F.R., Minoofar P.N. Bisphosphonates in the treatment of disorders of mineral metabolism. Adv. Endocrinol. Metab. 6:1995;259-288.
84. Smith J.A. Palliation of painful bone metastases from prostate cancer using sodium Etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J. Urol. 141:1989;85-87.
85. Spitzer W.O., Dobson A.J., Hall J., Chesterman E.et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J. Chron. Dis. 34:1981;585-597.
86. Stepan J., Pacovsky V., Horn V.et al. Relationship of the activity of the bone isoenzyme of serum alkaline phosphatase to urinary hydroxyproline excretion in metabolic and neoplastic bone diseases. Eur. J. Clin. Invest. 8:1978;373-377.
87. Thurlimann B., Morant R., Jungi W.F., Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support. Care Cancer. 2:1994;61-65.
88. Tong D., Gillick L., Hendrickson F. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer. 50:1982;893-899.
89. Twycross R.G., Fairfield S. Pain in far-advanced cancer. Pain. 14:1982;303-310.
90. Tyrrell C.T., Collinson M., Madsen E.L., Ford T.M., Coleman T. Intravenous Pamidronate: infusion rate and safety. Ann. Oncol. 5(Suppl. 7):1994;S27-S29.
91. Tyrrell, C.J., Bruning, P.F., May-Levin, F., et al., Pamidronate infusion as a single-agent therapy for bone metastases: a phase II trial in patients with breast cancer, Eur. J. Cancer, 31A/12 (1995) 1976-1980.
92. Uebelhart D., Gineyts E., Chapuy M.C. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Mineral. 8:1990;87.
93. van der Pluijm G., Vloedgraven H., van Beek E.et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98:1996;698-705.
94. van Holten-Verzantvoort A.T.M., Zwinderman A.H., Aaronson N.K.et al. The effect of supportive Pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur. J. Cancer. 27(5):1991;544-549.
95. van Holten-Verzantvoort A.T.M., Kroon H.M., Bijvoet O.L.M.et al. Palliative Pamidronate treatment in patients with bone metastases from breast cancer. J. Clin. Oncol. 11:1993;491-498.
96. van Holten-Verzantvoort A.T.M., Hermans J., Beex L.V.A.M., Blijham G.et al. Does supportive Pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur. J. Cancer. 32A:1996;450-454.
97. Vinholes J.J., Guo C.-Y., Purohit O.P., Eastell R., Coleman R.E. Metabolic effects of Pamidronate in patients with metastatic bone disease. Br. J. Cancer. 7:1996;1089-1095.
98. Vinholes, J.J., Guo, C.Y., Purohit, O.P., Eastell, R. and Coleman, R.E., Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy, J. Clin. Oncol., 15 (1) (1997a) 131-138.
99. Vinholes, J.J., Purohit, O.P., Abbey, M.E., Eastell, R. and Coleman, R.E., Relationships between biochemical and symptomatic response in a double-blind randomized trial of Pamidronate for metastatic bone disease, Ann. Oncol., (1997b) 1243-1250.
100. World Health Organization, WHO Handbook for Reporting Results of Cancer Treatment, Geneva Offset Publication No. 48, 1979.
101. Wuster C.H., Schoter K.H., Thiébaud D.et al. Methylpentylaminopropylidene bisphosphonate (BM 21 0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Mineral. 22:1993;77-85.